Section 232 of the Trade Expansion Act of 1962 authorizes the President to impose tariffs on imports that threaten national security. In April 2025, the first Trump administration Commerce Department announced a Section 232 investigation into pharmaceutical imports, arguing that dependence on foreign active pharmaceutical ingredient (API) and finished-drug supply chains presents a national-security vulnerability. The investigation was formally initiated April 30, 2026 and produced a final determination in Q2 2026 supporting tariff imposition on named pharmaceutical importers.
The tariff implementation follows a two-tranche timeline. The initial tranche of 17 named companies faces tariffs effective Friday July 31, 2026 on active pharmaceutical ingredient (API) and finished-drug imports depending on manufacturing-location documentation. The broader pharmaceutical industry faces a September 29, 2026 deadline for additional tariff applicability, with tariff rates in the 25% range depending on specific supply-chain configurations.
Peptide-and-obesity-relevant sponsors affected by or facing Section 232 exposure include Novo Nordisk (Wegovy/Ozempic semaglutide, primarily manufactured in Denmark), Eli Lilly (Zepbound/Mounjaro tirzepatide and Foundayo orforglipron, primarily manufactured in Ireland and Indiana), Merck (LIPFENDRA/enlicitide macrocyclic peptide PCSK9 inhibitor, manufacturing across US and Ireland), AstraZeneca (elecoglipron oral GLP-1 and broader biologics portfolio), Sanofi (Dupixent dupilumab and vaccines portfolio), AbbVie (Skyrizi and Rinvoq immunology franchise), Roche, Bristol-Myers Squibb, Amgen, Pfizer, and Biogen.
President Trump also announced Tuesday July 21, 2026 that imported generic drugs would face zero tariffs for two years starting August 2028, providing a runway before generic-drug tariff exposure begins. Stories here cover the Section 232 investigation timeline, tariff imposition dates, company-level manufacturing exposure, and industry response. See [[trump-administration]] and [[pharmaceutical-tariffs]] for adjacent threads.
The Section 232 pharmaceutical tariff structure took effect Friday July 31, 2026 for the 17 companies named in Annex III of the Trump administration Executive Order. Tariff structure: 100% duties on patented drug and active pharmaceutical ingredient (API) imports absent an onshoring agreement; companies that negotiated an onshoring agreement before the July 31 deadline receive a reduced 20% tariff. The broader pharmaceutical industry faces a September 29, 2026 deadline for additional tariff applicability at the higher rates. Generic pharmaceuticals, biosimilars, and their associated ingredients are expressly excluded from Section 232 at this time (President Trump separately announced Tuesday July 21 that imported generics would face zero tariffs for two years starting August 2028). Industry response ahead of the July 31 deadline: over $500 billion in announced US pharmaceutical manufacturing investment commitments per Trump administration reporting. Independent analyst tallies documented $370-480 billion in announced US pharma manufacturing investment for the 2025-2030 period. Companies affected include Novo Nordisk, Eli Lilly, Merck, AstraZeneca, Sanofi, AbbVie, Roche, Bristol-Myers Squibb, Amgen, Pfizer, and Biogen. Drawback relief provisions apply for API and finished-drug exports made from imported components. The tariff structure was formally imposed via the Executive Order 120 days before the July 31 effective date.
President Trump's Section 232 pharmaceutical tariffs took effect Friday July 31, 2026 for the 17 companies named in the initial tranche of the Section 232 national-security investigation. The Section 232 pathway allows the President to impose tariffs on imports that threaten national security; the pharmaceutical investigation was announced April 1, 2025 by the Commerce Department under the Trump administration and formally initiated April 30, 2026. Companies in the initial tranche face tariffs on active pharmaceutical ingredient (API) and finished-drug imports depending on manufacturing-location documentation; the broader pharmaceutical industry faces a September 29 deadline for additional tariff applicability. Peptide-and-obesity-relevant sponsors including Novo Nordisk (Wegovy/Ozempic semaglutide, primarily manufactured in Denmark), Eli Lilly (Zepbound/Mounjaro tirzepatide and Foundayo orforglipron, primarily manufactured in Ireland and Indiana), Merck (LIPFENDRA/enlicitide macrocyclic peptide PCSK9, manufacturing across US and Ireland), AstraZeneca (elecoglipron and biologics portfolio), Sanofi (Dupixent dupilumab), AbbVie (Skyrizi and Rinvoq), Roche, Bristol-Myers Squibb, Amgen, Pfizer, and Biogen all face potential 25% import duties depending on manufacturing-location documentation. President Trump also announced Tuesday July 21 that imported generic drugs would face zero tariffs for two years starting August 2028, providing a two-year runway before generic tariffs begin.
July 2026 closed as the most consequential peptide-and-obesity policy month in the site's coverage window. Regulatory milestones: the July 1 Medicare GLP-1 Bridge Program launch providing Wegovy (semaglutide), Zepbound KwikPen (tirzepatide), and Foundayo (orforglipron) at $50/month capped copay for approximately 3.8 million eligible Medicare Part D beneficiaries through December 31, 2027; the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) two-day session recommending 6 of 7 research peptides for the Section 503A Bulks List (BPC-157 8-6-1, KPV 8-6-1, TB-500 8-6, MOTS-c 7-5-2, Semax 8-5, Epitalon 7-4; Emideltide/DSIP rejected); the July 30 close of the 503B GLP-1 Bulks List exclusion comment period on the April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide; and the Section 232 pharmaceutical tariffs effective date July 31. Product milestones: the July 16 FDA approval of Merck LIPFENDRA (enlicitide) as the first once-daily oral macrocyclic peptide PCSK9 inhibitor (56-59% LDL reduction in CORALreef Phase 3, $315/month launch pricing); the July 7 FDA accelerated approval of Vera Therapeutics TRUTAKNA (atacicept-vymj) for primary IgA nephropathy; the July 17 FDA traditional approval of Novartis Fabhalta (iptacopan) for IgAN; the July 23 Arrowhead Redemplo (plozasiran) Phase 3 SHASTA-3 and SHASTA-4 positive readout (79-81% triglyceride reduction). Industry milestones: the July 19-20 Samsung Biologics $1.8 billion all-cash tender offer for PolyPeptide; the July 21 Novo Nordisk lawsuit and July 24 TRO filing against Eli Lilly over GLP-1 advertising; the July 20-23 EMA CHMP recommendation for lerodalcibep (Lyrokaul) monthly PCSK9 fusion protein.
President Donald Trump announced Tuesday July 21, 2026 via social media that imported generic drugs will face zero tariffs for two years starting August 1, 2026 before a 100% levy takes effect in August 2028 and rises to 200% one year later. Trump described the escalation as 'a penalty' for companies that do not build manufacturing plants in the US within the grace period. India is the largest exporter of generic medicines to the US ($10.5 billion in fiscal year 2024-25), with pharmaceuticals among India's top three exports to America. Companies with the greatest exposure include Teva, Viatris, and Apotex, all of which manufacture a large share of US-sold products overseas. Sandoz (Novartis' generic subsidiary), which had two Abbreviated New Drug Applications for generic tirzepatide (Mounjaro and Zepbound) accepted by the FDA on June 29, 2026, told CNBC it was 'too early to assess' the proposal because 'further details on the implementation and scope of the measure are still required.' The tariff timeline collides with the tirzepatide patent expiration (2036 in the US) and the Indian generic semaglutide launches from Biocon, Dr. Reddy's, and Hetero that rolled out in March-April 2026. Patented and branded drugs remain unchanged under the April 2 Section 232 100% patented pharma tariff.